You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial
|
|---|---|
| Published in |
Annals of Oncology, May 2019
|
| DOI | 10.1093/annonc/mdz082 |
| Pubmed ID | |
| Authors |
C. Santos, D. Azuara, J.M. Viéitez, D. Páez, E. Falcó, E. Élez, C. López-López, M. Valladares, L. Robles-Díaz, P. García-Alfonso, C. Bugés, G. Durán, A. Salud, V. Navarro, G. Capellá, E. Aranda, R. Salazar |
X Demographics
The data shown below were collected from the profiles of 7 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 6 | 86% |
| Unknown | 1 | 14% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 57% |
| Practitioners (doctors, other healthcare professionals) | 3 | 43% |
Mendeley readers
The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 49 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 12% |
| Student > Ph. D. Student | 5 | 10% |
| Other | 4 | 8% |
| Student > Postgraduate | 4 | 8% |
| Student > Master | 4 | 8% |
| Other | 11 | 22% |
| Unknown | 15 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 29% |
| Biochemistry, Genetics and Molecular Biology | 8 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
| Nursing and Health Professions | 2 | 4% |
| Unspecified | 1 | 2% |
| Other | 2 | 4% |
| Unknown | 19 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 March 2024.
All research outputs
#2,646,525
of 25,738,558 outputs
Outputs from Annals of Oncology
#1,442
of 7,897 outputs
Outputs of similar age
#55,395
of 364,453 outputs
Outputs of similar age from Annals of Oncology
#41
of 132 outputs
Altmetric has tracked 25,738,558 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,897 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.7. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 364,453 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 132 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.